Followers | 1693 |
Posts | 205379 |
Boards Moderated | 11 |
Alias Born | 01/02/2008 |
Wednesday, July 12, 2023 7:07:22 PM
Recent SXTP News
- First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind • GlobeNewswire Inc. • 06/27/2024 11:59:00 AM
- 60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis • GlobeNewswire Inc. • 06/11/2024 11:59:00 AM
- Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind • GlobeNewswire Inc. • 05/30/2024 11:59:00 AM
- 60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study • GlobeNewswire Inc. • 05/20/2024 11:59:00 AM
- 60 Degrees Pharmaceuticals Announces First Quarter 2024 Results • GlobeNewswire Inc. • 05/15/2024 05:45:03 PM
- 60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases • GlobeNewswire Inc. • 05/08/2024 11:59:00 AM
- 60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required • GlobeNewswire Inc. • 05/02/2024 11:59:00 AM
- 60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis • GlobeNewswire Inc. • 04/03/2024 11:58:00 AM
- 60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024 • GlobeNewswire Inc. • 03/14/2024 11:59:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:00:34 PM
- 60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris • GlobeNewswire Inc. • 02/20/2024 12:59:00 PM
- 60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer • GlobeNewswire Inc. • 02/08/2024 12:59:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 08:33:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 08:31:40 PM
- WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering • PR Newswire (US) • 01/31/2024 05:00:00 PM
- 60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering • GlobeNewswire Inc. • 01/31/2024 04:15:00 PM
- WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering • PR Newswire (US) • 01/30/2024 02:45:00 PM
- 60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering • GlobeNewswire Inc. • 01/30/2024 02:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/30/2024 05:15:25 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 10:01:11 PM
- 60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting • GlobeNewswire Inc. • 01/22/2024 12:59:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 07:56:53 PM
- 60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements • GlobeNewswire Inc. • 01/16/2024 12:59:00 PM
- 60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024 • GlobeNewswire Inc. • 12/26/2023 12:59:00 PM
- 60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease • GlobeNewswire Inc. • 11/15/2023 12:29:00 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM